Efficacy of ZR2 regimen in the treatment of refractory diffuse large B-cell lymphoma in the elderly
-
摘要: 目的 观察泽布替尼联合来那度胺及利妥昔单抗(ZR2方案)治疗老年难治性弥漫大B细胞淋巴瘤(DLBCL)的近期疗效及不良反应。方法 采用ZR2方案(泽布替尼320 mg/d，口服，第1~21天; 来那度胺25 mg/d，口服，第1~14天; 利妥昔单抗375 mg/m2，静脉滴注，第0天)治疗20例年龄>65岁的难治性DLBCL患者，21 d为1个疗程，持续6~8个周期，达完全缓解后给予来那度胺单药维持治疗。结果 20例患者共完成90个疗程，中位疗程数5(2~8)个，总有效率为75.0%(15/20)，其中完全缓解率为65.0%(13/20)，≥80岁患者的完全缓解率为75.0%(6/8)。乳酸脱氢酶≥245 U/L与 < 245 U/L、双表达(DEL、c-Myc≥40%伴Bcl-2≥50%)与无双表达(non-DEL)患者的完全缓解率比较，差异均无统计学意义(P＞0.05)。中位随访5.5(3~8)个月，总生存率为90.0%，中位无进展生存期及中位总生存期均未达到。不良反应主要为血液系统不良反应，大多在Ⅱ级及以下水平，经治疗后好转; 治疗及随访期间未出现严重的心脏(如心律失常、心房颤动、心力衰竭) 毒性及肾脏功能异常等不良反应。结论 ZR2方案治疗老年难治性DLBCL安全、耐受且具有一定疗效，可作为临床合适的治疗选择。Abstract: Objective To observe the short-time effects and adverse events of zanubrutinib combined with lenalidomide and rituximab(ZR2) for elderly patients with refractory diffuse large B-cell lymphoma(DLBCL).Methods A total of 20 patients(more than 65 years old) with refractory DLBCL who had received R-miniCHOP for at least 2 cycles but did not achieve complete remission or developed rapidly after a brief complete remission were treated with ZR2(zanubrutinib 320 mg/d, oral, day 1-21; lenalidomide 25 mg/d, oral, day 1-14; rituximab 375 mg/m2, iv drip, day 0). 21 days was a course of treatment, lasting for 6-8 cycles. After achieving complete remission, patients were given lenalidomide single drug for maintenance treatment.Results The 20 patients completed total of 90 cycles, at the 5 median courses, the overall response rate at the end of induction phase was 75.0%(15/20), 13 patients(65.0%) achieved complete response. The complete response rate was 75.0%(6/8) in patients older than 80 years. There was no significant difference in the complete remission rate between patients with lactate dehydrogenase≥245 U/L and < 245 U/L, double expression(DEL, c-Myc≥40% and Bcl-2≥50%) and non-double expression(non-Del)(P> 0.05). The median follow-up was 5.5(3-8) months. The overall survival rate was 90.0%. The median progression free survival and median overall survival were not achieved. The main adverse events were hematological adverse events, which were mostly in gradeⅡand below, and improved after treatment. There were no serious adverse events such as cardiac toxicity(arrhythmia, atrial fibrillation, heart failure), abnormal renal function during treatment and follow-up.Conclusion ZR2 regimen is safe, tolerable and effective in the treatment of senile refractory DLBCL, which can be used a suitable choice for clinical treatment.
-
Key words:
- zanubrutinib /
- diffuse large B-cell lymphoma /
- elderly patients /
- efficacy /
- adverse events
-
-
表 1 20例DLBCL患者的疗效分析
例(%) 特征 例数 CR/例(%) P 性别 0.160 男 11 9(81.8) 女 9 4(44.4) 年龄 0.642 < 80岁 12 7(58.3) ≥80岁 8 6(75.0) 亚型 >0.999 GCB 10 7(70.0) non-GCB 10 6(60.0) B症状 0.374 有 11 7(63.6) 无 9 6(66.7) LDH/(U·L-1) 0.160 ≥245 9 4(44.4) < 245 11 9(81.8) β2微球蛋白/(mg·L-1) 0.642 ≥3 12 7(58.3) < 3 8 6(75.0) 双表达 0.613 否 14 10(71.4) 是 6 3(50.0) 
下载: 导出CSV
-
[1] Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity[J]. Blood, 2015, 125(1): 22-32. doi: 10.1182/blood-2014-05-577189
[2] 徐卫, 梁金花. 弥漫大B细胞淋巴瘤新基因分型及分子靶向的治疗进展[J]. 临床血液学杂志, 2020, 33(9): 594-598. https://t.cnki.net/kcms/detail?v=znUxuWmAUtc_T_InIGHX1l4JOjJGxl3t8s91HW6dTDfoU3AnOMeeifa-U5lcuGT2hKJhUm8ndwzXGM0InRevNLiOX2y6IJr0B4XIlXdTKxOA9Z9ntWEiM4C6F2-LhVqS&uniplatform=NZKPT
[3] Issa DE, van de Schans SA, Chamuleau ME, et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010[J]. Haematologica, 2015, 100(4): 525-533. doi: 10.3324/haematol.2014.107300
[4] Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes[J]. CA Cancer J Clin, 2016, 66(6): 443-459. doi: 10.3322/caac.21357
[5] Tavares A, Moreira I. Diffuse large B-cell lymphoma in very elderly patients: Towards best tailored treatment-A systematic review[J]. Crit Rev Oncol Hematol, 2021, 160(2): 1032-1039.
[6] Thieblemont C, Bernard S, Meignan M, et al. Optimizing initial therapy in DLBCL[J]. Best Pract Res Clin Haematol, 2018, 31(3): 199-208. doi: 10.1016/j.beha.2018.08.001
[7] Nowakowski GS, Blum KA, Kahl BS, et al. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research[J]. J Natl Cancer Inst, 2016, 108(12): 257-261. doi: 10.1093/jnci/djw257
[8] Syed YY. Zanubrutinib: First Approval[J]. Drugs, 2020, 80(1): 91-97. doi: 10.1007/s40265-019-01252-4
[9] Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase[J]. J Hematol Oncol, 2016, 9(1): 80-87. doi: 10.1186/s13045-016-0313-y
[10] Beltran BE, Castro D, Paredes S, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2020, 95(4): 435-445. doi: 10.1002/ajh.25760
[11] 张慕晨, 钱樱, 郝杰, 等. 二线方案治疗98例复发难治弥漫大B细胞淋巴瘤的疗效及预后分析[J]. 中华血液学杂志, 2017, 38(6): 511-516.
[12] Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias[J]. Hematol Oncol, 2017, 35 Suppl 1: 37-45.
[13] Davies K, Barth M, Armenian S, et al. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2020, 18(8): 1105-1123. doi: 10.6004/jnccn.2020.0036
[14] Sorigue M, Orna E, Sancho JM. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review[J]. Leuk Lymphoma, 2018, 59(11): 2602-2611. doi: 10.1080/10428194.2018.1448085
[15] 邵奕, 唐善浩, 陆滢, 等. R-CDOP方案治疗大包块和(或)结外多部位累及的弥漫大B细胞淋巴瘤患者2年疗效和安全性观察[J]. 临床血液学杂志, 2020, 33(7): 481-485, 492. https://t.cnki.net/kcms/detail?v=znUxuWmAUtd0ER9dUdJGXtkiXOgw3h-ReX8v2u1H697YvVyiLwL-Ss6oiWYy640FCQmfhLD1HqLippPB-02mUDFeKUOeYTLhxwRpbOrs2hU0uJPjnI8pyjuWiQBQT1Vd&uniplatform=NZKPT
[16] Yamasaki S, Matsushima T, Minami M, et al. Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study[J]. Eur Geriatr Med, 2022, 13(1): 195-201. doi: 10.1007/s41999-021-00539-8
[17] Hounsome L, Eyre TA, Ireland R, et al. Diffuse large B cell lymphoma(DLBCL)in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England[J]. Br J Cancer, 2022, 126(1): 134-143. doi: 10.1038/s41416-021-01525-4
[18] Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase Ⅱ clinical trial[J]. Leukemia, 2013, 27(9): 1902-1909. doi: 10.1038/leu.2013.95
[19] Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL[J]. Blood, 2019, 134(13): 1024-1036. doi: 10.1182/blood.2018891598
[20] Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma[J]. Blood Rev, 2017, 31(2): 37-42. doi: 10.1016/j.blre.2016.09.004
[21] Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program[J]. Blood, 2013, 121(20): 4021-4250. doi: 10.1182/blood-2012-10-460063
[22] Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J]. J Clin Oncol, 2012, 30(28): 3452-3459. doi: 10.1200/JCO.2011.41.0985
[23] Patel KK, Isufi I, Kothari S, et al. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2020, 61(14): 3387-3394. doi: 10.1080/10428194.2020.1808208
[24] Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R(etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study[J]. Lancet Haematol, 2018, 5(12): e609-e617. doi: 10.1016/S2352-3026(18)30177-7
[25] Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis[J]. Blood, 2014, 124(15): 2354-2361. doi: 10.1182/blood-2014-05-578963
[26] Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis[J]. Br J Haematol, 2015, 170(4): 504-514. doi: 10.1111/bjh.13463
[27] El-Sharkawi D, Basu S, Ocampo C, et al. Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy[J]. Leuk Lymphoma, 2012, 53(10): 1949-1952. doi: 10.3109/10428194.2012.679360
[28] Iioka F, Izumi K, Kamoda Y, et al. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy[J]. Int J Clin Oncol, 2016, 21(3): 498-505. doi: 10.1007/s10147-015-0912-6
[29] Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future[J]. Cancer J, 2019, 25(6): 386-393. doi: 10.1097/PPO.0000000000000412
-